On-Demand Content | Virtual Event

Pharmaceutical companies are investing more resources in investigator-initiated trials (IITs) as they strive to expand their commercial opportunities. Yet as organizations strive to improve and expand their IIT programs, they are struggling to ensure IIT proposals align with corporate objectives and also demonstrate scientific merit. A significant increase in the number of IIT submissions necessitates that organizations manage their IIT programs effectively to not let costs leapfrog results.
IITs are perceived as a relatively low-cost source of clinical data. They might in this way find answers to questions that were not part of the company’s original clinical development plan. This type of interaction represents an opportunity for pharmaceutical companies to enrich their strategic planning by selecting studies that might help to identify new targets, indications, subpopulations, and other advances. It should be, therefore, part of the company’s strategy to identify new opportunities through IITs. The decision to fund these projects requires deep medical insight and knowledge combined with the ability to think out of the box: a role for which consistency can be covered only under the guidance of medical affairs.

This event is designed to help pharma companies understand the wide-ranging opportunities within IITs, and demonstrate why the decision for investment in any of these trials should be based on a structured strategic plan by building a dedicated team to manage IITs to ensure that the investigators keep up the deal at their end by working with them and making sure they stay on track to complete the study.

SPEAKER HIGHLIGHTS

Dr. Deepak Bunger, MD
Dr. Deepak Bunger, MD
General Manager, Medical Affairs and Clinical Development

TORRENT PHARMACEUTICALS

Stephanie Daub (Ebner)
Stephanie Daub (Ebner)
Director, Field Medical Excellence

ALKERMES

Kathryn Josephs
Kathryn Josephs
Director, ISR/NRDG, Medical Affairs

MIRATI THERAPEUTICS

Jeremy Keeton
Jeremy Keeton
ONC IIT Advisor

ELI LILLY

Jennifer Kellen
Jennifer Kellen
Director, Investigator Grants

EXELIXIS

Kat Long
Kat Long
Pronouns: she, her, hers - Director, Medical Affairs Operations

ALKERMES

Kathleen Maley
Kathleen Maley
SLRM, Associate Director

MERCK

Scott McConnell
Scott McConnell
Vice President Medical Affairs

CHIASMA

Alan Minsk
Alan Minsk
Partner and Leader, Food and Drug Practice Team

ARNALL GOLDEN GREGORY LLP

Tammy Moll
Tammy Moll
SLRM Lead, Associate Director

MERCK

Lillian Phan
Lillian Phan
Associate Director, ISR & CU Program Operations, Global Medical Affairs

BEIGENE

Amy Place
Amy Place
Global Medical Affairs

SCHOLAR ROCK

Dr. Oscar Segurado
Dr. Oscar Segurado
Chief Medical Officer

ASC THERAPEUTICS

Sloan Stribling, PMP
Sloan Stribling, PMP
Associate Director, General Medicine Team Lead – Scientific Leadership and Research Manager

MERCK

Viraj Suvarna
Viraj Suvarna
MD, Pharmacology MSc

PHARMACEUTICAL MEDICINE

Michael Worden
Michael Worden
Senior Investigator Grants Manager

EXELIXIS

Christina (Cwalinski) Zukowski
Christina (Cwalinski) Zukowski
Medical Investigator Sponsored Studies Operations Manager

IPSEN BIOPHARMACEUTICALS

Top Reasons to Purchase

  1. Improve your Investigator-Initiated Research Strategy by Leveraging Data Insights and Clinical Research Expertise
  2. Learn How to Interpret Clinical Trial Data and Review Investigator-Initiated Research Proposals to Redefine Safety and Effectiveness Information
  3. Develop Enhanced Standard Operating Procedures (SOPs) to Ensure Standardization of Study Procedures
  4. Evaluate and Approve IIT Proposals in an Expedited and More Efficient Manner, While Staying Compliant
  5. Build Essential KOL Relationships and Optimize Thought Leader Management for Optimal Clinical Support
  6. Engaging Knowledgeable and Experienced Researchers to Provide a “Second Set of Eyes” and Assure IIT Soundness and Feasibility

Who Should Purchase

  • Investigator-Initiated Trials (IIT), Research and Studies
  • Investigator-Initiated Research and Studies (IIRS)
  • Investigator Initiated Studies (IIS)
  • Medical Affairs
  • MSLs/Medical Communication
  • Collaborative Studies
  • Research Grants
  • Scientific Engagement
  • Global Medical Research Operations
  • External Operations & Sourcing
  • Compliance, Legal and Regulatory
  • Contract Administration
  • Clinical Trial Liaison
  • Clinical Trial Monitoring/Management
  • Clinical Data Analysis
  • Clinical Affairs
  • Clinical Research
  • Marketing Services
  • Medical Clinical Operations
  • Vendor Management